Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cytori Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: SnowShredder who wrote (215)	10/15/2009 12:24:27 PM
From: SnowShredder	Read Replies (1) \| Respond to of 251

In the US... prweb.com Best of Luck, SS >>>>>>>>> Introducing Stem Cell Breast Augmentation Arizona Surgeon, First in the US to Pioneer Procedure that has Gained World Notoriety Scottsdale, AZ (PRWEB) October 15, 2009 -- Todd K. Malan, M.D., board certified cosmetic surgeon, has pioneered a revolutionary new procedure, the Natural Breast Augmentation, which employs the latest technologic advances in fat harvesting, adult stem cell transfers and breast splinting technology to provide women the option of enlarging their breasts using their own fat. The technique results in breasts that look and feel smoother than conventional cosmetic surgery using implants. Stem cells enable the fat to grow its own blood supply, thus becoming an integral part of the breast rather than a foreign lump. Stem cells have the potential to change into any cells in the body; they are found in most tissues, especially fat. Autologous fat transfer for breast augmentation and reconstruction has remained a highly debated and controversial procedure following the introduction of these techniques in the U.S. in the late 1980's. "Yet, recent advances in fat harvesting and transfer techniques, digital mammography, and the use of adipose derived adult stem and regenerative cells necessitate a re-examination of this longstanding bias against fat transfer breast augmentation," says Malan. Yet, recent advances in fat harvesting and transfer techniques, digital mammography, and the use of adipose derived adult stem and regenerative cells necessitate a re-examination of this longstanding bias against fat transfer breast augmentation With Natural Breast Augmentation, fat is harvested and collected with Body-Jet fat harvesting device utilizing saddlebags, love handles, lower abdomen, buttocks and thighs for sites of fat donation. The procedure is unique in that we use the latest technologic advances in fat harvesting as well as adult stem cell transfers. Cell-enhanced reconstruction uses adipose fat that is a rich source of stem and regenerative cells. These stem cells are not the controversial embryonic stem cells. This new procedure uses a special process to ensure that the transplanted cells will live and adapt to the transplantation site (breasts). The process was developed by Cytori, and uses a machine called CelutionTM System EU. After fat removal, the cells are transferred to the Cytori Celution System which is used to separate regenerative and stem cells from fat cells. The regenerative and stem cells are then washed, concentrated, and enzyme activated. The activated stem cell mixture is then combined with the fat cells and then injected into fat that is already present in the breast where it fills in and replaces tissue volume. The injection of the fat along with the stem cells results in a permanent 250cc to 500cc overall breast size increase, allowing for a 1 or 2 bra cup size increase. A pressure splint is then used after the procedure to ensure that the fat remains in place and assists in promoting regeneration of the transferred fat and stem cells. There are several advantages to Natural Breast Augmentation. Saline or silicone implants which are considered the standard for cosmetic breast augmentation and reconstruction show complication rates to be as high as 25% with a re-operation rate of 100% at 10 years. Additionally, implants can obscure 15-50% of normal breast tissue on screening mammography making early detection or follow-up of cancer difficult. Fatty tissue does not exhibit reactive inflammation, rejection, or autoimmune disease. Natural Breast Augmentation results in excellent cosmetic result including a natural feel to the breasts that is reproducible and permanent. Unlike implants this procedure will not interfere with future mammograms. The procedure, performed in conjunction with liposuction allows artistic body re-contouring to complement breast augmentation for a new total-body look.

To: SnowShredder who wrote (215)	1/8/2010 10:50:59 AM
From: SnowShredder	Respond to of 251

FDA Grants 510(k) Marketing Clearance for Cytori's PureGraft System; First & Only Device on Market for Aesthetic Body Contouring using Autologous Fat Grafts finance.yahoo.com Best of Luck, SS >>>>>>>> FDA Grants 510(k) Marketing Clearance for Cytori's PureGraft System; First & Only Device on Market for Aesthetic Body Contouring using Autologous Fat Grafts Press Release Source: Cytori Therapeutics On Friday January 8, 2010, 8:00 am EST SAN DIEGO--(BUSINESS WIRE)--The FDA has granted Cytori Therapeutics (NASDAQ: CYTX - News) 510(k) marketing clearance for its PureGraft™ System. Cytori will now launch the first and only device in the United States cleared for aesthetic body contouring using autologous fat. PureGraft™ allows a patient’s own fat tissue to rapidly be prepared in approximately 15 minutes for re-injection back into the same patient for aesthetic contouring. PureGraft™ is able to prepare both small and large volumes of fat grafting tissue ranging from 50 mL to 250 mL. Puregraft™ maintains sterility while optimizing the yield of tissue to be grafted, which provides significant utility to physicians. In contrast to traditional methods of graft preparation, PureGraft™ washes the graft and drains the tumescent fluid, free lipid and debris in a closed sterile system, allowing for a cleaner graft in less time than it would take to prepare a comparable volume of graft tissue traditionally. “FDA clearance provides us with a strategically important product in addition to the CelBrush™ to help establish our brand and build relationships with U.S. plastic and reconstructive surgeons,” said Marc H. Hedrick, M.D., President of Cytori Therapeutics. “There are several advantages this product offers physicians performing autologous fat grafts, which can improve efficiencies in the operating room, decrease surgery time and, by being able to process greater volumes, to include large defects.” PureGraft™ will be sold in the United States directly by Cytori as well as through select distribution partners on a non-exclusive basis. The product will be available in the first quarter of 2010 and will be formally launched at the American Society of Aesthetic Plastic Surgeons in May 2010. Cytori is also seeking marketing approval (CE Mark certification) for PureGraft™ in Europe, which is expected in the first half of 2010. In Europe, PureGraft™, in addition to being sold as a standalone product, will be used to complement Cytori’s currently available autologous tissue processing system as a means to expand the potential number of clinical applications. According to the American Society of Plastic Surgeons’ most recent report of plastic surgery statistics, over 46,000 fat grafting procedures were performed in the United States in 2008. Currently, over 5,000 plastic surgeons are registered with the American Society of Plastic Surgeons. About Cytori Cytori is an emerging leader in providing patients and physicians around the world with medical technologies, which harness the potential of adult regenerative cells from adipose tissue. The Celution® System family of medical devices and instruments is being sold into the European and Asian cosmetic and reconstructive surgery markets but is not yet available in the United States. Our StemSource® product line is sold globally for cell banking and research applications. <snip>